Matches in Nanopublications for { ?s ?p "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP308439.RAR9LaB4NWgx1ow47V-rXKIcB2VPkjsg45tK7-BRNzFq4130_assertion description "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308439.RAR9LaB4NWgx1ow47V-rXKIcB2VPkjsg45tK7-BRNzFq4130_provenance.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion description "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_provenance.
- NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_assertion description "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248307.RAGok0vvdcjgbm1DGnGaU5Vuz3LZf30Flb9KscCORwlDE130_provenance.
- NP1248305.RAy34mHc6Wh6DOT81gtwSCgJkM8CtFUhwilUMvpn1ukVw130_assertion description "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1248305.RAy34mHc6Wh6DOT81gtwSCgJkM8CtFUhwilUMvpn1ukVw130_provenance.